Physician profile
Michael Y Lee
NPI 1942293451
$6,213.92
in general payments reported to CMS, 2019-2025
30 companies · $1,385 in 2025
The $1,385 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,122 · 2020: $246 · 2021: $99.50 · 2022: $562 · 2023: $1,242 · 2024: $1,558 · 2025: $1,385.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,185.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,185.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,167.02 | 2019-2025 | |
| Novo Nordisk INC | $799.72 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $632.07 | 2019-2025 | Evenity, Repatha, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $533.94 | 2019-2025 | Jardiance |
| Abbvie INC. | $491.96 | 2019-2025 | |
| Gilead Sciences, INC. | $444.15 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $324.51 | 2019-2025 | Farxiga, Fasenra |
| Exact Sciences Corporation | $246.79 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Merck Sharp & Dohme LLC | $224.74 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
| Lilly USA, LLC | $196.39 | 2023-2025 | Zepbound, Mounjaro |
| Janssen Pharmaceuticals, INC | $191.36 | 2019-2023 | Xarelto |
| Coherus Oncology, INC. | $125.00 | 2024 | |
| Novartis Pharmaceuticals Corporation | $118.95 | 2022-2023 | |
| E.R. Squibb & Sons, L.L.C. | $115.22 | 2019-2023 | Eliquis |
| Revance Therapeutics, INC. | $86.74 | 2025 | Daxxify |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $70.91 | 2019-2023 | Shingrix |
| Myriad Women'S Health, INC. | $70.08 | 2023 | Myrisk |
| Galderma Laboratories, L.P. | $59.43 | 2021-2024 | |
| Dexcom, INC. | $43.59 | 2024 | Dexcom G6 Transmitter |
| Stryker Corporation | $39.30 | 2025 | Triathlon |
| Allergan, INC. | $35.15 | 2019-2021 | |
| Edwards Lifesciences Corporation | $30.34 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Kowa Pharmaceuticals America, INC. | $29.27 | 2024-2025 | Zoryve |
| Hologic Sales and Service, LLC | $24.11 | 2025 | Aptima |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.92 | 2025 | Xifaxan |
| Medtronic USA, INC. | $19.78 | 2019 | |
| Bausch Health US, LLC | $18.40 | 2019 | |
| Sanofi Pasteur INC. | $18.00 | 2019 | |
| Ibsa Pharma INC. | $17.46 | 2023 | Tirosint, Licart |
| Therapeuticsmd, INC. | $16.62 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.